Engineered T-Cells take on childhood leukemia in early trial

NCT ID NCT01683279

Ongoing Disease control Sponsor: Seattle Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a child's own immune cells, genetically modified to recognize and attack leukemia cells, are safe and can be given in the right dose. Six children and young adults with CD19-positive acute lymphoblastic leukemia that has returned after treatment will receive these modified T-cells. The main goal is to find the safest dose and watch for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically modified T-cells (CAR T-cells) that target CD19 on leukemia cells
What this could lead to: If successful, this could lead to a new treatment option for children with leukemia that has come back after standard therapy.
What could go wrong: This is a very early, small phase 1 trial with only 6 participants, focused on safety. The treatment may not work or could cause severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Leukemia, B-Cell Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL LEUKEMIA

Contacts and locations

Locations

Seattle Children's Hospital

Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.